FindTrial
Sign In

Effect of dopamine medicine in Parkinskon Disease patients assessed through objective auditory tests

ABR rate function and general MLR characteristics in individuals with PD.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/09/036740
Enrollment
15
Registered
2021-09-22
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G20- Parkinsons disease

Interventions

Intervention1: NIL: NIL

Sponsors

Febin Joseph
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Participants whom are typical PD. Newly diagnosed. Age range between > 50 years of age Subjects with hearing loss less than 30dBHL Normal middle ear function Age and gender matched Adults above 50 years of age. Normal middle ear function Hearing loss less than 30 dBHL

Exclusion criteria

Exclusion criteria: Participants who are already on medication or medication other than levodopa for PD. Participants who are Parkinson with syndrome diagnosed by neurologist. Age and gender matched Adults below 50 years of age. Middle ear dysfunction Hearing loss more than 30 dBHL

Design outcomes

Primary

MeasureTime frame
Amplitude and Latency function of ABR and MLRTimepoint: 6 months—

Secondary

MeasureTime frame
nilTimepoint: nil—

Countries

India

Contacts

Public ContactDr Hari Prakash

Manipal College of health profession

hari.prakash@manipal.edu9886135522

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026